EF
EW icon

Empirical Finance’s Edwards Lifesciences EW Stock Holding History

Empirical Finance’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Buy
21,246
+665
+3% +$55.7K 0.08% 211
2026
Q1 		$1.65M Sell
20,581
-43
-0.2% -$3.54K 0.08% 218
2025
Q4 		$1.76M Sell
20,624
-901
-4% -$73.9K 0.08% 198
2025
Q3 		$1.67M Buy
21,525
+196
+0.9% +$15.3K 0.08% 218
2025
Q2 		$1.67M Buy
21,329
+134
+0.6% +$9.99K 0.09% 206
2025
Q1 		$1.54M Buy
21,195
+461
+2% +$33K 0.09% 202
2024
Q4 		$1.53M Sell
20,734
-273
-1% -$19.1K 0.09% 190
2024
Q3 		$1.39M Buy
21,007
+452
+2% +$32.8K 0.08% 214
2024
Q2 		$1.9M Sell
20,555
-1,491
-7% -$132K 0.12% 153
2024
Q1 		$2.11M Buy
22,046
+732
+3% +$61.5K 0.13% 158
2023
Q4 		$1.63M Buy
21,314
+155
+0.7% +$10.8K 0.11% 168
2023
Q3 		$1.47M Buy
21,159
+1,751
+9% +$141K 0.11% 168
2023
Q2 		$1.83M Buy
19,408
+2,192
+13% +$191K 0.14% 136
2023
Q1 		$1.42M Buy
17,216
+831
+5% +$65.3K 0.13% 145
2022
Q4 		$1.22M Buy
16,385
+1,318
+9% +$102K 0.13% 155
2022
Q3 		$1.25M Buy
15,067
+2,497
+20% +$240K 0.15% 138
2022
Q2 		$1.2M Buy
12,570
+688
+6% +$71.2K 0.15% 132
2022
Q1 		$1.4M Buy
11,882
+1,273
+12% +$143K 0.16% 121
2021
Q4 		$1.37M Buy
10,609
+2,841
+37% +$331K 0.16% 117
2021
Q3 		$879K Buy
7,768
+450
+6% +$51.4K 0.13% 156
2021
Q2 		$758K Buy
7,318
+1,010
+16% +$95.2K 0.12% 194
2021
Q1 		$575K Hold
6,308
– – 0.1% 191
2020
Q4 		$575K Buy
6,308
+1,112
+21% +$92.2K 0.1% 191
2020
Q3 		$415K Buy
5,196
+1,126
+28% +$87.9K 0.09% 195
2020
Q2 		$281K Buy
4,070
+449
+12% +$31.9K 0.07% 206
2020
Q1 		$228K Buy
+3,621
New +$261K 0.07% 194
2017
Q1 		– Sell
-276
Closed -$9K – 246
2016
Q4 		$9K Buy
+276
New +$8.94K 0.01% 393

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Empirical Finance's EW Position: Q2 2026 in Review

Empirical Finance increased its Edwards Lifesciences (EW) stake by 3.2% in Q2 2026, buying an estimated $55.7K and bringing the position to 21,246 shares worth $1.92M. The position accounts for 0.08% of the portfolio, ranked #211.

Empirical Finance first reported a position in EW in Q4 2016 and has held it in 27 quarters since. The position peaked at $2.11M in Q1 2024. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Empirical Finance held 21,246 shares of Edwards Lifesciences worth $1.92M as of Q2 2026.
  • Empirical Finance bought 665 Edwards Lifesciences shares in Q2 2026, an estimated $55.7K.
  • Edwards Lifesciences made up 0.08% of Empirical Finance's portfolio in Q2 2026, its #211 holding.
  • Empirical Finance first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 27 quarters since.
  • Empirical Finance's Edwards Lifesciences position peaked at $2.11M in Q1 2024.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Empirical Finance's 13F filing for Q2 2026, filed 14 Aug 2026.